BrainQ is a technology company.
BrainQ has raised $49.0M across 2 funding rounds.
BrainQ has raised $49.0M in total across 2 funding rounds.
BrainQ has raised $49.0M in total across 2 funding rounds.
BrainQ's investors include Hanaco Ventures, Defy Partners, OurCrowd, Supernode Ventures, Underscore.
BrainQ Technologies is a healthtech company developing AI-powered neuromodulation therapies and a connected virtual care platform to restore brain function, primarily targeting stroke recovery.[1][2] Its lead product, the Q Therapeutic System, uses frequency-tuned electromagnetic field (EMF) therapy delivered via a home-use wearable device to improve motor function, independence, and return-to-work rates for ischemic stroke patients, earning FDA Breakthrough Device Designation, CE Mark, and World Economic Forum Technology Pioneer status.[1][2][5] BrainQ serves stroke patients through premium provider networks like concierge medicine and neuro-rehab clinics, addressing the leading cause of long-term disability with non-invasive, evidence-based neuroprotection and neurorecovery; recent milestones include a $40M raise, first patient enrollment in the pivotal EMAGINE trial, and Fast Company "Next Big Things in Tech" recognition.[1][2]
Founded in Jerusalem, Israel, BrainQ emerged from research into AI-driven, non-invasive brain therapies, with CEO and Co-founder Yotam Drechsler leading the mission to "cure stroke disability."[2] The idea stemmed from pilot studies, including a 2022 randomized controlled trial (Weisinger et al.) demonstrating EMF therapy's efficacy in sub-acute stroke motor recovery, building on evidence of oscillating fields aiding neuroprotection via gene expression and network rebalancing.[3] Early traction included FDA Breakthrough Designation for its stroke product, partnerships via platforms like OurCrowd for funding, and selection as a World Economic Forum Technology Pioneer, humanizing its focus on brain longevity therapeutics amid global stroke impacts.[1][2][4][5]
BrainQ rides the bioelectric medicine and AI-neuromodulation wave, targeting a $50B+ stroke rehab market amid aging populations and rising ischemic stroke incidence (leading global disability cause).[1][2] Timing aligns with post-COVID telehealth acceleration and wearable tech maturity, amplified by FDA fast-tracks for breakthroughs; market forces like reimbursement shifts and AI integration favor non-invasive alternatives to invasive stimulators or drugs.[1][3] It influences the ecosystem by pioneering brain longevity therapeutics, fostering provider networks, and validating EMF for neurology—potentially expanding to other indications via its platform, as seen in WEF recognition and trial progress.[2][5]
BrainQ is poised for commercialization post-EMAGINE trial results, scaling home therapy via provider partnerships and reimbursement pathways while expanding its pipeline.[1][3] Trends like AI-agent marketing, wearable bioelectronics, and precision neurology will propel growth, with influence evolving toward dominating stroke recovery and brain health ecosystems. As a pioneer restoring independence for millions, BrainQ exemplifies healthtech's shift from treatment to true functional cure.[1][2]
BrainQ has raised $49.0M across 2 funding rounds. Most recently, it raised $40.0M Series B in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $40.0M Series B | Hanaco Ventures | |
| May 1, 2018 | $9.0M Series A | Defy Partners, OurCrowd, Supernode Ventures, Underscore |